Vitrolife's Q1 report came in largely in line with consensus showing organic growth of 5% in local currencies, though a -9% FX headwind obscures this in reported SEK terms. We expect making minor downward estimate revisions as the FX-component have been a larger factor than our model assumes. We expect a broadly neutral share price reaction on the report.
LÄS MER
